Enter the last name, specialty or keyword for your search below.
Barbara Lynn Stauch Slusher, M.A.S., Ph.D.
Barbara Slusher, Ph.D., MAS, is Professor of Neurology (primary), Medicine, Psychiatry, and Neuroscience at Johns Hopkins School of Medicine and the Director of Johns Hopkins Drug Discovery
Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from Johns Hopkins School of Medicine while simultaneously earning her Master's degree in Administrative Science from the Johns Hopkins Carey School of Business (formerly the Hopkins' School of Continuing Studies).
Before joining Johns Hopkins in 2010, Dr. Slusher spent 18 years in the pharmaceutical industry, including several years at the level of Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through early clinical development and was involved in the successful development, launch and/or post marketing support of several branded medicines including Quetiapine (Seroquel TM) for schizophrenia, Palonosetron (Aloxi TM) for chemotherapy-induced nausea and vomiting, Azacytodine (Dacogen TM) for myelodysplastic syndrome, and Fospropofol (Lucedra TM) for monitored anesthesia care (MAC) sedation.
At Johns Hopkins, she leads the largest integrated drug discovery program on campus, responsible for translating basic science discoveries at Hopkins into novel small molecule therapeutics. Her veteran drug discovery team consists of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic/drug metabolism experts, with an average of 15 years Pharma R&D drug discovery experience.
She has also published over 175 scientific articles and is the inventor on 75 issued patents and applications. She co-founded a new biotechnology company in Baltimore called Cerecor and is leading the first-ever International Consortium of over 130 Academic Drug Discovery Centers with over 1500 members in an effort to coordinate and enhance university-led drug discovery efforts.
Barbara Slusher can be reached via email at bslusher@jhmi.edu.
At Johns Hopkins Dr. Slusher currently leads a 20-member veteran drug discovery team of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic/drug metabolism experts, who are engaged in identifying novel drug targets arising from JHU faculty’s research and translating them into new drug therapies for neurological disorders.
Dr. Slusher is a member of the JHU NIMH Center for Novel Therapeutics of HIV-associated Cognitive Disorders, and serves as the Director for the Therapeutics Development Core. It is through this center that novel therapies that evolve from JHU studies will be evaluated for neuroprotective activity in cell culture and animal models of neurodegeneration for HIV-associated cognitive disorders and dementia. Promising compounds with in vivo efficacy and favorable pharmacokinetics and safety properties may ultimately be evaluated in clinical studies as adjunctive therapy for HIV patients with cognitive disorders.
Dr. Slusher has published over 120 scientific articles and is the inventor on 52 patents and patent applications. She has been an invited speaker at over 40 national and international scientific meetings and has served on the board or as a scientific consultant of multiple biotechnology companies. She is leading the first National Consortium for Academic Drug Discovery scientists in an effort to coordinate and enhance university-led drug discovery efforts. Most recently she has co-founded an new biotechnology company called Cerecor, to commercialize JHU drug discovery inventions.
Lab Website: Johns Hopkins Drug Discovery
Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Traystman RJ, Robinson MB, Britton P, Lu M, Tortella FC, Wozniak K, Yudkoff M, Jackson PF. "An inhibitor of NAAG hydrolysis prevents ischemic glutamate release and provides neuroprotection." Nature Medicine, 1999, 5:1396-1402
Rojas C, Stathis M, Thomas AG, Massuda E, Alt J, Zhang J, Luby T, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher BS. "Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor." Anesthesia and Analgesia, 2008 Aug; 107(2):353-5
Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS, Coyle JT. "Rat brain N-acetylated alpha-linked acidic dipeptidase activity: purification and immunologic characterization." J.Biol Chem, 1990, 265(34):21297-21301
Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. "Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells." The Prostate 2000, 45: 350-354
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV. "Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells." Cell Metabolism, 2012, 15(1):110-21
A Changing Ecosystem for Drug Discovery, Doorways to Discovery (November 2014)
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
